The Science of Therapeutic Peptides · Volume IX
Companion: Peptide-Adjacent Compounds, Formulation & Laboratory Practice
Peptide-adjacent compounds, formulation, and laboratory practice.
27 chapters
- IX.1Manufacturing and Verifying Therapeutic PeptidesSynthesis, purity, potency, and product quality
- IX.2Regulation, Access, and the Peptide MarketplaceHow peptide products move from discovery to the shelf — and what the labels actually mean
- IX.3The Global Therapeutic Peptide IndustryMarkets, companies, economics, and competitive strategy
- IX.4The Therapeutic Peptide Production EcosystemPharmaceutical Companies, Compounders, Contract Manufacturers, and Alternative Supply Channels
- IX.5Manufacturing Therapeutic PeptidesFacilities, equipment, inputs, processes, scale-up, and commercial production
- IX.6When Peptide Production Goes WrongImpurities, contamination, sterility failures, and patient risk
- IX.7Testing Therapeutic PeptidesAnalytical methods, certificates of analysis, independent verification, and laboratory reliability
- IX.8AICARThe nucleoside that taught cells to act as if they were running out of energy
- IX.95-amino-1MQA methyl group, a metabolic thermostat, and the small molecule built to jam it
- IX.10AndarineS-4 / GTx-007 — an early arylpropionamide discontinued for enobosarm
- IX.11BAM-15A drug with no receptor, and the poison it was built to replace
- IX.12CardarineGW501516 — a PPAR-δ agonist that is not a SARM
- IX.13L-CarnitineThe muscle extract that became a vitamin, then a shuttle, then a suspect
- IX.14LigandrolLGD-4033 between a 21-day healthy-men RCT and a grey-market DILI case layer
- IX.15Lipo-C / MIC B12A Nobel-grade discovery history, a rodent deficiency model, and a clinic injection the evidence never caught up with
- IX.16MetforminFrom goat’s rue to first-line diabetes, AMPK lore, and the still-pending TAME bet
- IX.17Methylene blueFrom a coal-tar dye to a mitochondrial redox shuttle
- IX.18MK-677The once-daily pill that raised growth hormone for years — and never became a medicine
- IX.19OstarineEnobosarm between cancer cachexia, breast programmes, and GLP-1 lean-mass preservation
- IX.20PNC-27A fragment of the guardian gene, a door punched in the cancer-cell membrane, and how far a striking result reaches when no person has yet been treated
- IX.21RAD140Testolone / vosilasarm between a breast-cancer Phase 1 and a consumer safety case layer
- IX.22RapamycinSirolimus between ITP mouse lifespan and the thinner human healthy-aging record
- IX.23S-23A preclinical arylpropionamide with contraception animal data and almost no human efficacy package
- IX.24SARMsSelective androgen receptor modulators, the clinical residue, and the grey-market fog
- IX.25SLU-PP-332An estrogen-related-receptor agonist, and the biology of an “exercise mimetic”
- IX.26TesofensineA neurodegeneration drug that found its purpose in the wrong organ
- IX.27YK-11A steroidal partial AR agonist whose myostatin lore outruns the human evidence